Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective and Observational Study for Safety and Effectiveness Evaluation of Rhofanib® (Tofacitinib) in Patients With Alopecia.

NCT07101471 is registered in ClinicalTrials.gov with NanoAlvand as lead sponsor.

NCT NCT07101471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective and Observational Study for Safety and Effectiveness Evaluation of Rhofanib® (Tofacitinib) in Patients With Alopecia.
Lead sponsor
NanoAlvand
Phase
Observational
Overall status
Completed
Start date
August 4, 2020
Completion date
June 11, 2025
Enrollment
296 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata(aa), alopecia totalis/universalis